Reagents for measuring a therapeutic antibody rather than a target: why an anti-idiotype antibody, an anti idiotype antibody, an anti idiotypic antibody, an idiotype antibody, an idiotypic antibody, an anti-id antibody, an anti id antibody and the anti-idiotype antibodies sold as a pair are the only reagents that can distinguish your molecule from the patient's own immunoglobulin, how an anti-drug antibody, an anti drug antibody, an antidrug antibody, an anti-drug antibody assay and an anti drug antibody assay measure the response against it, what a neutralizing antibody assay, a cell based neutralizing antibody assay, cell based assays generally and an antibody neutralization assay add that a binding assay cannot, where an antibody binding assay, an antibody assay, antibody assays generally, an antibody search engine used to find the reagent and an spr antibody measurement sit in characterisation, and why antibody concentration, an antibody dilution calculator, antibody dilution buffer choice and antibody isotyping are the unglamorous parts that decide whether any of it is comparable

Building the bioanalytical package

1. Commission the idiotype pair early. Two reagents recognising different regions of the variable domain, one for capture and one for detection, are what make a quantitative assay possible. They take months to generate and sit on the critical path of every study that needs them.
2. Design for drug tolerance. Circulating drug binds the antibodies you are trying to detect. Acid dissociation and other pretreatments are what let the assay see them, and the tolerance achieved has to be measured and reported.
3. Confirm neutralisation functionally. A binding assay shows that an antibody response exists; a cell based assay shows whether it blocks activity. They answer different questions and regulators expect the second where the first is positive.
4. Fix the concentration method. Absorbance, colorimetric assay and immunoassay give different numbers for the same material. Pick one, state it, and use it consistently, because concentration errors propagate into every downstream calculation.
5. Validate against a written protocol. Accuracy, precision, selectivity, dilutional linearity, stability and a stated range, agreed before the assay is used. An assay validated after a surprising result is validated to explain it.

The reagent is the long pole

Everything in this package depends on having reagents that recognise your molecule specifically. Those reagents are generated to order, take months and cannot be bought from a catalogue, which is why bioanalytical readiness is a common cause of study delay.

Start the reagent programme when the molecule is chosen, not when the study is scheduled. It is the single most effective schedule protection available here.

Interference is the recurring theme

Drug interferes with the immunogenicity assay, target interferes with the pharmacokinetic assay, and endogenous immunoglobulin interferes with both. Every method in this area is built around a specific interference and has to demonstrate it was handled.

Report the tolerance achieved alongside the result. A result without it cannot be interpreted by anyone else.

Common questions

Why does an anti-idiotype reagent take so long to make?

Because it has to bind one variable region and nothing else, which requires immunisation or selection against that molecule and extensive counter screening. It is a discovery project, not a catalogue purchase, and it belongs early in a programme's plan.

What is drug tolerance and why does it matter?

It is the concentration of circulating drug at which the assay can still detect antibodies against it. Without adequate tolerance the assay reports negatives from samples that are positive, which is the most consequential failure in this area.

Binding or neutralising assay?

Both, in sequence. Binding assays screen; neutralising assays characterise the positives functionally. Reporting a binding result as evidence of neutralisation is not supported.

Browse by service class

• Compare Gene synthesis on advertised prices